Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis

Clin Pharmacokinet. 2020 Mar;59(3):297-309. doi: 10.1007/s40262-019-00840-7.

Abstract

The clinical pharmacology of elagolix was extensively evaluated in clinical studies in healthy subjects and in women with endometriosis. Elagolix pharmacokinetics (PK) show significant population variability, however they are minimally affected by patients' baseline characteristics and demographics, except for clinically relevant extrinsic and intrinsic factors such as coadministrated strong organic anion transporting polypeptide (OATP) 1B1 inhibitors and severe hepatic impairment, which are contraindications for the use of elagolix. These studies enabled a comprehensive understanding of elagolix mechanism of action and the downstream pharmacodynamic (PD) effects on gonadotropin and ovarian hormones, as well as full characterization of the PK/PD (PKPD) relationships of elagolix at various dosages, including the approved 150 mg once daily and 200 mg twice daily dosing regimens for the management of moderate to severe pain associated with endometriosis. Several model-based analyses have contributed to understanding of the benefit-risk profile of elagolix in patients with endometriosis, through characterization of the exposure relationship with responder rates, with changes in bone mineral density over time, as well as the interaction with coadministered drugs. Collectively, these studies and analyses served as supportive evidence for the effectiveness of the approved dosages and provided general dosing instructions of the first approved oral gonadotropin-releasing hormone receptor antagonist.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Oral
  • Bone Density / drug effects
  • Drug Interactions / physiology
  • Endometriosis / complications
  • Endometriosis / drug therapy*
  • Endometriosis / metabolism
  • Female
  • Gonadotropin-Releasing Hormone / drug effects
  • Hormone Antagonists / administration & dosage
  • Hormone Antagonists / pharmacokinetics*
  • Hormone Antagonists / pharmacology
  • Humans
  • Hydrocarbons, Fluorinated / administration & dosage
  • Hydrocarbons, Fluorinated / pharmacokinetics*
  • Hydrocarbons, Fluorinated / pharmacology
  • Liver Diseases / complications
  • Organic Anion Transporters / antagonists & inhibitors*
  • Organic Anion Transporters / metabolism
  • Pain / drug therapy
  • Pain / etiology
  • Pharmacogenetics
  • Pharmacology, Clinical
  • Pyrimidines / administration & dosage
  • Pyrimidines / pharmacokinetics*
  • Pyrimidines / pharmacology
  • Receptors, LHRH / antagonists & inhibitors*
  • Treatment Outcome

Substances

  • GNRHR protein, human
  • Hormone Antagonists
  • Hydrocarbons, Fluorinated
  • Organic Anion Transporters
  • Pyrimidines
  • Receptors, LHRH
  • Gonadotropin-Releasing Hormone
  • elagolix